Pembrolizumab: 33% response rate in advanced melanoma
Immunotherapy with the PD-1 inhibitor pembrolizumab yielded a 33% overall response rate, a 35% progression-free survival rate at 1 year, and a median overall survival of 23 months in 655 patients with advanced melanoma, according to a report published online in JAMA.
The agent generally was well...
Source: Skin and Allergy News - Category: Dermatology Source Type: news
More News: Allergy | Allergy & Immunology | Dermatology | Immunotherapy | Melanoma | Skin | Skin Cancer